Who Owns Haleon Company?

Haleon Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Haleon?

Understanding Haleon's ownership is key to grasping its strategy and governance. The company emerged from a spin-off from GlaxoSmithKline (GSK) in July 2022, becoming an independent public entity.

This significant demerger, which also incorporated Pfizer's consumer health division, established a major global consumer healthcare firm. Haleon is renowned for its extensive range of everyday health products, including popular brands like Sensodyne and Advil.

Who owns Haleon?

Haleon's initial ownership structure was established through a joint venture between GSK and Pfizer's consumer healthcare divisions, forming the company in 2019. This foundation set the stage for its eventual independent public offering.

Formation of Haleon

Haleon was created in 2019 as a joint venture combining the consumer healthcare businesses of GSK and Pfizer.

Independent Listing

The company became an independent entity with its listing on the London Stock Exchange and New York Stock Exchange on July 18, 2022.

Initial Ownership Distribution

Following the demerger, GSK initially held approximately 68% of the joint venture, with Pfizer holding the remaining 32%.

Post-Spin-off Holdings

After the spin-off, GSK retained about 13.6% of Haleon's shares, while Pfizer maintained its 32% stake.

Parent Company Intentions

Both GSK and Pfizer indicated plans to gradually reduce their ownership to concentrate on their core pharmaceutical and vaccine operations.

Founding Stakeholders

GSK and Pfizer were the primary early stakeholders, reflecting their contributions of consumer health assets to the new company.

The early ownership of Haleon was significantly influenced by its formation as a joint venture. GSK contributed the majority of assets, leading to its larger initial stake. Pfizer's participation established it as a key early shareholder. This structure provided the foundation for Haleon's subsequent journey as an independent, publicly traded entity, allowing investors to examine Target Market of Haleon.

Haleon's Genesis

Haleon's origins lie in the strategic combination of GSK and Pfizer's consumer health businesses.

• The joint venture was established in 2019.
• Haleon became an independent company on July 18, 2022.
• It is publicly traded on the London and New York stock exchanges.
• GSK and Pfizer were the initial major shareholders.

Haleon SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Haleon has undergone a significant transformation since its demerger from GSK in July 2022. Initially listing with a market capitalization around £30.5 billion, both GSK and Pfizer have progressively reduced their holdings, leading to a more diversified shareholder base.

Following its demerger, Haleon's ownership structure has evolved significantly as its former parent companies, GSK and Pfizer, have systematically reduced their stakes. GSK completed its exit in May 2024 by selling its final 4.2% stake for approximately £1.25 billion. Pfizer, which initially held a 32% stake, also divested its shares, completing its full exit in March 2025 after selling its remaining 7.3% stake for about £2.5 billion. This strategic divestment by both entities has paved the way for Haleon to establish a more independent and diversified shareholder profile, with institutional investors now comprising the majority of its ownership.

Haleon's Evolving Shareholder Landscape

Haleon's ownership has shifted dramatically since its independence, with former parent companies exiting their stakes. Institutional investors now dominate the shareholder base, signaling a new era for the company's strategic direction.

• GSK sold its final 4.2% stake in May 2024.
• Pfizer completed its full exit from Haleon in March 2025.
• Institutional investors collectively hold approximately 75% of Haleon's shares.
• Major asset managers like BlackRock are among the key institutional shareholders.
• This shift supports Haleon's focus on standalone growth strategies, a key element in its Marketing Strategy of Haleon.

Haleon PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors for Haleon is composed of both executive and independent non-executive members, ensuring a diverse range of expertise in its governance. Sir Dave Lewis leads the board as Chair, with Brian McNamara serving as the Chief Executive Officer.

Haleon's voting power is primarily distributed through its ordinary shares, with each share typically granting one vote. As of April 30, 2025, the company had 9,016,910,492 ordinary shares with voting rights. This figure was 9,053,360,882 as of October 31, 2024. Holders of Haleon American Depositary Receipts (ADRs) can direct JPMorgan on how to vote their underlying shares. Following a reduction in Pfizer Inc.'s stake to below 20%, Pfizer's representatives, David Denton and Bryan Supran, concluded their board tenures in December 2024 and February 2025, respectively, reflecting shifts in Haleon ownership. The company has not experienced any significant proxy battles or activist investor campaigns recently, indicating stable corporate governance. Understanding the Mission, Vision & Core Values of Haleon can provide further insight into the company's strategic direction and how its board operates.

Key Governance and Ownership Details

Haleon's board structure and voting rights are central to its corporate governance. Changes in major shareholdings directly influence board composition.

• Each ordinary share carries one vote.
• ADR holders can instruct voting via JPMorgan.
• Board representation adjusted due to reduced major shareholder stakes.
• No recent proxy battles reported.

Haleon Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Haleon's ownership structure has undergone significant transformation due to strategic divestments by its former parent companies, GSK and Pfizer. These actions have resulted in a more dispersed shareholder base for Haleon, marking its transition to a fully independent entity.

Haleon has actively managed its capital structure, notably through share repurchase programs. In March 2025, the company bought back approximately 44.14 million ordinary shares from Pfizer for around £170 million ($220 million) as part of a larger £500 million repurchase plan for 2025. This move underscores Haleon's commitment to returning value to its shareholders. This trend of spinning off consumer health units to enhance strategic focus is also observed in other major pharmaceutical companies, such as Johnson & Johnson and Sanofi.

Haleon's Financial Performance

For the full year 2024, Haleon reported total sales of £11.23 billion ($14.6 billion). The company has set an objective for organic revenue growth between 4% and 6% for 2025.

Market Position and Strategy

As of August 21, 2025, Haleon's market capitalization was $44.05 billion. The company's stated mission is to deliver better everyday health, with its governance and financial reporting reflecting its independent public status. Understanding Haleon's strategic direction involves looking at its Competitors Landscape of Haleon.

Haleon Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔